Physician profile
Benjamin Horowitz
NPI 1013545292
$1,058.11
in general payments reported to CMS, 2019-2025
10 companies · $814 in 2025
The $814 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $122 · 2024: $122 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,058.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $302.29 | 2025 | |
| Glaxosmithkline, LLC. | $244.07 | 2023-2024 | Jesduvroq |
| Amgen INC. | $150.00 | 2025 | |
| Janssen Biotech, INC. | $145.62 | 2025 | Tremfya, Simponi Aria |
| Aurinia Pharma U.S., INC. | $77.42 | 2025 | Lupkynis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $74.22 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.28 | 2025 | |
| Novo Nordisk INC | $17.05 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.30 | 2025 | Relistor |
| Opko Pharmaceuticals, LLC | $13.86 | 2025 | Rayaldee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Horowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.